Syndax Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Syndax Pharmaceuticals
SNDX Stock  USD 12.61  0.43  3.30%   
Syndax Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Syndax Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Syndax Pharmaceuticals financial statements helps investors assess Syndax Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Syndax Pharmaceuticals' valuation are summarized below:
Gross Profit
-218.8 M
Market Capitalization
1.1 B
Enterprise Value Revenue
37.3557
Revenue
23.7 M
Earnings Share
(3.72)
We have found one hundred twenty available fundamental trend indicators for Syndax Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Syndax Pharmaceuticals current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 615.3 M in 2025. Enterprise Value is likely to drop to about 533.4 M in 2025

Syndax Pharmaceuticals Total Revenue

29.85 Million

Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.6 K, Interest Expense of 5.2 M or Selling General Administrative of 126.9 M, as well as many indicators such as Price To Sales Ratio of 52.11, Dividend Yield of 0.0198 or PTB Ratio of 4.12. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Syndax Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets761.1 M724.8 M241.5 M
Slightly volatile
Short and Long Term Debt Total9.3 M12.1 M10.1 M
Slightly volatile
Other Current Liabilities83.3 M79.3 M17.2 M
Slightly volatile
Total Current Liabilities108.7 M103.5 M30.8 M
Slightly volatile
Property Plant And Equipment Net2.1 M2 M660 K
Slightly volatile
Current Deferred Revenue47.1 M44.8 M12.8 M
Slightly volatile
Accounts Payable12.2 M11.6 M4 M
Slightly volatile
Cash86.5 M154.1 M69.4 M
Slightly volatile
Non Current Assets Total127.8 M121.8 M19.6 M
Slightly volatile
Non Currrent Assets Other206.2 K217 K1.3 M
Pretty Stable
Cash And Short Term Investments601.5 M572.9 M216.3 M
Slightly volatile
Common Stock Shares Outstanding43 M85.4 M43.2 M
Pretty Stable
Short Term Investments439.7 M418.8 M142.2 M
Slightly volatile
Liabilities And Stockholders Equity761.1 M724.8 M241.5 M
Slightly volatile
Non Current Liabilities Total241.1 M229.6 M39.3 M
Slightly volatile
Other Current Assets19.5 M18.6 M4.3 M
Slightly volatile
Other Stockholder Equity1.6 B1.5 B570.1 M
Slightly volatile
Total Liabilities458.5 M436.7 M83.3 M
Slightly volatile
Property Plant And Equipment Gross2.6 M2.4 M792 K
Slightly volatile
Total Current Assets633.2 M603.1 M221.9 M
Slightly volatile
Short Term Debt13.2 M12.6 M8.8 M
Slightly volatile
Common Stock Total Equity7.2 K6.9 K3.3 K
Slightly volatile
Common Stock9.4 K9 K3.7 K
Slightly volatile
Other Liabilities14.2 M13.4 M9.7 M
Slightly volatile
Long Term Debt400.4 M381.3 M99.4 M
Slightly volatile
Net Receivables11.8 M11.2 M1.9 M
Slightly volatile
Deferred Long Term Liabilities20.2 M19.3 M10.9 M
Slightly volatile
Short and Long Term Debt14.6 M13.9 M5.4 M
Slightly volatile
Preferred Stock Total Equity264.2 M375.3 M271.7 M
Slightly volatile
Property Plant Equipment1.3 M1.2 M452.2 K
Slightly volatile
Capital Surpluse669.6 M1.1 B603.6 M
Slightly volatile
Non Current Liabilities Other776.8 K817.6 K1.1 M
Pretty Stable
Net Invested Capital349.7 M631.8 M226.4 M
Slightly volatile
Net Working Capital332.7 M499.5 M223.5 M
Slightly volatile
Capital Stock6.3 K9 K3.9 K
Slightly volatile
Capital Lease Obligations1.3 M2.1 M1 M
Slightly volatile
Long Term Debt Total20.8 M22.9 M18.7 M
Slightly volatile

Syndax Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.6 K8 K42.4 K
Very volatile
Selling General Administrative126.9 M120.9 M30.3 M
Slightly volatile
Other Operating Expenses381.5 M363.4 M102.2 M
Slightly volatile
Research Development253.7 M241.6 M71.1 M
Slightly volatile
Total Operating Expenses380.7 M362.5 M102.1 M
Slightly volatile
Interest Income27.4 M26.1 M5.8 M
Slightly volatile
Reconciled Depreciation7.6 K8 K60.7 K
Slightly volatile

Syndax Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation45.2 M43 M11.7 M
Slightly volatile
Begin Period Cash Flow310.4 M295.6 M74.4 M
Slightly volatile
Other Cashflows From Financing Activities371 M353.4 M60.1 M
Slightly volatile
Depreciation7.6 K8 K42.4 K
Very volatile
Total Cash From Financing Activities371 M353.4 M117.8 M
Slightly volatile
End Period Cash Flow86.6 M154.3 M69.4 M
Slightly volatile
Sale Purchase Of Stock27.1 M28.6 M39.3 M
Pretty Stable
Change To Netincome8.2 M16.1 M6.7 M
Slightly volatile
Dividends Paid2.1 M2.3 M2.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio52.1154.85202
Slightly volatile
Dividend Yield0.01980.02230.0243
Slightly volatile
Days Sales Outstanding209199122
Very volatile
Stock Based Compensation To Revenue3.932.094.2099
Slightly volatile
Capex To Depreciation6.446.143.7042
Slightly volatile
EV To Sales45.5647.96178
Slightly volatile
Payables Turnover0.07040.0710.0736
Pretty Stable
Sales General And Administrative To Revenue10.875.8712.0819
Slightly volatile
Research And Ddevelopement To Revenue11.1511.7417.8337
Pretty Stable
Capex To Revenue0.0010.00110.0533
Slightly volatile
Cash Per Share4.126.70565.1945
Slightly volatile
Days Payables Outstanding4.9 K5.1 K23.3 K
Slightly volatile
Income Quality0.630.86240.7813
Pretty Stable
Current Ratio6.995.82398.1088
Slightly volatile
Receivables Turnover1.81.924.0924
Pretty Stable
Capex Per Share0.00620.00430.0055
Slightly volatile
Revenue Per Share0.340.250.2734
Slightly volatile
Interest Debt Per Share0.190.19954.6164
Slightly volatile
Debt To Assets0.01590.01671.5379
Slightly volatile
Graham Number7.358.279.019
Slightly volatile
Days Of Payables Outstanding4.9 K5.1 K23.3 K
Slightly volatile
Ebt Per Ebit1.180.93841.0971
Slightly volatile
Quick Ratio6.945.82038.0517
Slightly volatile
Net Income Per E B T1.091.111.0044
Slightly volatile
Cash Ratio2.51.4882.9035
Slightly volatile
Days Of Sales Outstanding209199122
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0175
Slightly volatile
Fixed Asset Turnover15.110.5413.9955
Pretty Stable
Debt Ratio0.01590.01671.5379
Slightly volatile
Price Sales Ratio52.1154.85202
Slightly volatile
Asset Turnover0.04240.02940.0352
Slightly volatile
Gross Profit Margin1.081.111.0051
Slightly volatile

Syndax Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap615.3 M1.1 B510.4 M
Slightly volatile
Enterprise Value533.4 M987.5 M438.7 M
Slightly volatile

Syndax Fundamental Market Drivers

Cash And Short Term Investments572.9 M

Syndax Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue44.8 M47.1 M
Total Revenue23.7 M29.8 M
Cost Of Revenue826 K784.7 K
Stock Based Compensation To Revenue 2.09  3.93 
Sales General And Administrative To Revenue 5.87  10.87 
Research And Ddevelopement To Revenue 11.74  11.15 
Revenue Per Share 0.25  0.34 
Ebit Per Revenue(12.91)(13.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY